
Professional statement
Mr Simon Bott is a leading consultant urologist, practicing in Surrey as a founding member of Urology Partners. He has a specialist interest in the diagnosis and treatment of prostate cancer and also provides a range of treatments for kidney stones, bladder cancer, erectile dysfunction, incontinence, kidney cancer, and urinary tract infections. He has access to all the latest techniques to deal with kidney stones, both surgical and non-surgical.
Mr Bott qualified in 1994 from St Bartholomew’s and the Royal London Hospitals, then completed six years of basic surgical training around London. He was awarded an MD from the University of London in 2003 for his research into prostate cancer, which was followed by five years of specialist training in urology. In 2008 Mr Bott was appointed consultant at Frimley Health Trust, where he set up the trust’s lithotripsy service and acts as the Trust's lead for stone surgery and urological cancer.
As the principal investigator on a number of trials, Mr Bott continues to conduct research into prostate cancer, and has published over 40 papers and books on the subject. He and his colleagues were the first in Europe to describe template prostate biopsies to assist in the diagnosis of prostate cancer. He is currently exploring ways to improve the diagnosis process through multiparametric MRI scans and fusion guided biopsies, and is involved with early trials in focal therapy.
Clinics

Urology Partners
Frimley, Portsmouth Rd, GU16 7UJMedical insurances accepted
Credentials
Professional experience
- 32 years of experience
- Consultant Urologist, Urology Partners | The Parkside Suite Frimley (present)
Subspecialties
- Kidney stones
- Prostate cancer
Professional memberships
- Fellow of the Royal Society of Medicine Section of Urology
- Fellow of the Royal College of Surgeons
Education
- FEBU, European Board of Urology (2008)
- FRCS(Urol) (2007)
Publications and conferences
- Prostate cancer detection using quantitative T2 and T 2 -weighted imaging: The effects of 5-alpha-reductase inhibitors in men on active surveillance. Giganti F, Gambarota G, Moore CM, Robertson NL, McCartan N, Jameson C, Bott SRJ, Winkler M, Whitcher B, Castro-Santamaria R, Emberton M, Allen C, Kirkham A.
J Magn Reson Imaging. 2018 Jun;47(6):1646-1653.
- MRI findings in men on active surveillance for prostate cancer: does dutasteride make MRI visible lesions less conspicuous? Results from a placebo-controlled, randomised clinical trial.
Giganti F, Moore CM, Robertson NL, McCartan N, Jameson C, Bott SRJ, Winkler M, Gambarota G, Whitcher B, Castro R, Emberton M, Allen C, Kirkham A.
Eur Radiol. 2017 Nov;27(11):4767-4774. doi: 10.1007/s00330-017-4858-0. Epub 2017
Prizes and awards
- The Derek Packham Memorial Gold Medal, 2004
- British Urological Foundation/AstraZeneca Scholarship, 2001
Languages spoken
- English
- French
Reviews
- Would you recommend this doctor?
- Treatment of the doctor
- Treatment of the staff
- Waiting time
- Condition of facilities